Paul Hastings Advised Underwriters on CymaBay Therapeutics, Inc.’s $258.75 Million Follow-On Offering
Paul Hastings LLP advised Piper Sandler and Raymond James as representatives of the several underwriters in connection with CymaBay Therapeutics, Inc.’s $258.75 million follow-on offering of common stock and pre-funded warrants, including full exercise of the underwriters’ option to purchase additional shares. CymaBay Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need.
Partner and co-head of Equity Capital Markets and co-chair of the Corporate Life Sciences Group Seo Salimi and Securities and Capital Markets partner Will Magioncalda led the Paul Hastings team.
More details on the transaction can be found here.
With widely recognized elite teams across 17 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world's leading investment banks, asset managers and corporations.